News | January 21, 2022
Biocon consolidated PAT at Rs 187.1 cr. in Q3FY22
Biocon has reported consolidated financial results for the period ended December 31, 2021
Biocon has reported consolidated financial results for the period ended December 31, 2021
The companies were evaluated via a comprehensive, in-depth assessment process that included a sustainability framework of 300 points each for – Purpose, Partnership, Planet and People
Victor Chang Cardiac Research Institute (VCCRI) researcher recognized for his influential work on cardiovascular disease
CuraTeQ and Orion had entered into a licensing agreement, granting marketing and distribution rights for CuraTeQ’s biosimilar products under development in the Nordic states, Austria, Hungary and Slovenia
Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones
The first pilot study from India analyzing Covaxin-Covishield mixed doses
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
The Indian Council of Medical Research (ICMR), intends to enter into non-exclusive agreements with companies
Results from the ongoing vodobatinib clinical study are being presented for the second consecutive year at the ASH annual meeting, underlining the promising potential of the drug for the treatment of heavily pre-treated CML
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
Subscribe To Our Newsletter & Stay Updated
